Xin Lang Cai Jing·2025-09-09 02:16Company Overview - CanSino Biologics, established on January 13, 2009, is located in the Tianjin Economic and Technological Development Zone and specializes in the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [2] - The company was listed on August 13, 2020, and its main business revenue composition is 97.84% from vaccine and related product sales, with 2.16% from other supplementary sources [2] Stock Performance - As of September 9, CanSino's stock price increased by 42.31% year-to-date, with a 3.53% rise over the last five trading days, a 5.31% increase over the last 20 days, and a 44.66% increase over the last 60 days [2] - The stock was trading at 86.88 CNY per share, with a market capitalization of 21.498 billion CNY [1] Financial Performance - For the first half of 2025, CanSino reported a revenue of 382 million CNY, reflecting a year-on-year growth of 26.00%, while the net profit attributable to the parent company was -13.4854 million CNY, showing a significant year-on-year improvement of 94.02% [2] - The company has distributed a total of 198 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Market Activity - On September 9, the net inflow of main funds into CanSino was 4.8775 million CNY, with large orders accounting for 17.60% of purchases and 18.15% of sales [1]